An observational study in COVID-19, sponsored by Chinese University of Hong Kong. Recruiting at 10 sites in 3 countries. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-08.
Sponsored by Chinese University of Hong Kong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in COVID-19 by Chinese University of Hong Kong — 3 open to participants now, 8 under way, none of them phase 3. COVID-19 · Chinese University of Hong Kong.
Among the 21 studies in COVID-19 by Chinese University of Hong Kong, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2020, is one of 15 observational ones, and was the 6th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →3 of the 21 studies in COVID-19 by Chinese University of Hong Kong are open now, in 3 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18–65
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 7 started in 2020.
This study's planned enrollment of 3,000 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 82 across the 6 interventional studies, 200 across the 15 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in COVID-19 by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05787327Chinese University of Hong KongRCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19 | 2027-04-30 |
| NCT04950803Chinese University of Hong KongA Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in COVID-19 by Chinese University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.
With over 10 million individuals infected worldwide, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health crisis. It is recognized that pregnant women are at an increased risk of acquiring viral respiratory infection and developing severe pneumonia due to the physiologic changes in their immune and cardiopulmonary systems. Previous studies have attempted to determine maternal and perinatal outcome and potential risk of vertical transmission in pregnant women affected by COVID-19, however, relevant clinical data and biological samples have not been collected in a systematic manner. The research project will engage in collaborative research across obstetricians/maternal-fetal medicine subspecialists, gynecologist, infectious disease specialists, pediatrician, developmental and molecular biologists and bioinformatician between the CUHK, China and Spain. The objectives of this proposal are to: 1) determine the rate of SARS-CoV-2 seroconversion in unselected pregnant women in Hong Kong; 2) determine the rate of SARS-CoV-2 infection in women presenting with miscarriage and stillbirth; 3) follow the pregnancy course and perinatal outcome of confirmed COVID-19-infected pregnant cases; 4) determine the risk and characteristics of vertical transmission; and 5) evaluate the placental barrier, immune response and fetal damage in vertical transmission of SARS-CoV-2. A series of longitudinal and cross-sectional observational studies, and a laboratory-based study will be conducted to fulfil the 5 objectives.
Results generated will inform obstetrics and gynecology, pediatric and infectious disease scientific communities as well as public health specialists and policy makers regarding: (1) the estimated seroconversion rate in women of childbearing age; these results will help (i) improve the approach to care for pregnancy and childbirth during the COVID-19 outbreak; and (ii) formulate preventive measures to be implemented specifically for pregnant women in reducing risk of infection and associated complications to both the women and their unborn child; (2) the impact of COVID-19 on maternal and perinatal outcomes; data from high-quality research will inform practice during the COVID-19 outbreak, guiding healthcare professionals on how to adjust the management approach to infected pregnant women and the exact risks the infection poses to the babies; (3) the risk of vertical transmission at different stages of pregnancy and its sequelae; findings of this study will guide counselling, decision making and clinical management; (4) the identification of cellular site of viral entry and replication in the maternal-fetal interface that would be instrumental in designing therapeutic measures to cease vertical transmission and developing therapeutic treatments.
Pregnant women
Objective 1: Seroconversion during pregnancy
Inclusion criteria:
Objective 2: SARS-CoV-2 and pregnancy loss
Inclusion criteria:
•Pregnant women presenting with first and second trimester miscarriage in Hong Kong and Spain, as well as those with stillbirth during periods of 6 and 12 months, respectively.
Objective 3: Pregnancy course and perinatal outcome
Inclusion criteria:
•Pregnant women affected by COVID-19
Objective 4: Vertical transmission
Inclusion criteria:
•Pregnant women affected by COVID-19
Objective 5: Potential mechanisms for vertical transmission
Inclusion criteria:
•Pregnant women affected by COVID-19
It's an observational study, no intervention involves.
Seroconversion during pregnancy - DSS1
Mother
Time frame: At DSS1 (Around 11-13 weeks gestation)
Seroconversion during pregnancy - At delivery
Mother
Time frame: At Delivery
Pregnancy loss
Mother (1st); Mother and abortus/stillborn baby(2nd)
Time frame: At pregnancy loss
Pregnancy course and perinatal outcome
Mother and Baby
Time frame: From date of recruited until the date of delivery
Vertical transmission
Mother and Baby
Time frame: At Newborn 0 hours of life, mother immediately after delivery
Vertical transmission
Mother and Baby
Time frame: At Newborn 7 days of life
Vertical transmission
Mother and Baby
Time frame: At Newborn 14 days of life
Vertical transmission
Mother and Baby
Time frame: At Newborn 6 months of life
Vertical transmission
Mother and Baby
Time frame: At Newborn 18 months of life
Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection.
Mother and Baby
Time frame: through study completion, up to 2 years
Started May 2020 (actual). Primary completion is estimated for Apr 2024, 47 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 47 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →